(Q39000212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

review article

1 reference

title

Telotristat ethyl: a new option for the management of carcinoid syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Angela Lamarca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Juan W Valle

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

16 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

26 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

2487-2498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

26 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Metastatic carcinoid tumors and the malignant carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Bradykinin in carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Quality of life after treatment of neuroendocrine liver metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Long-term serotonin effects in the rat are prevented by terguride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Development and characterization of a novel in vivo model of carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Fibrosis and carcinoid syndrome: from causation to future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

5-HT is a potent relaxant in rat superior mesenteric veins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Pharmacology of serotonin: what a clinician should know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Constitutively Elevated Blood Serotonin Is Associated with Bone Loss and Type 2 Diabetes in Rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

A mouse model of carcinoid syndrome and heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1254191

10.1080/14656566.2016.1254191

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27817224%20AND%20SRC:MED&resulttype=core&format=json